Analyst Research

Report Title Price
Provider: ValuEngine, Inc.
$25.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S Issues FY 2013 Guidance Below Analysts' Estimates


Thursday, 7 Mar 2013 11:01am EST 

Genmab A/S announced that for fiscal 2013, it expects Revenue to be in the range of DKK540-DKK580 and operating loss continuing operations to be in the range of DKK(40)-DKK(90). According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of DKK602 million and EBIT of DKK(5) for fiscal 2013. 

Company Quote

253.7
1.3 +0.52%
4:16am EDT